Personal information

Emails & domains

Verified email addresses

Other IDs

Scopus Author ID: 36990126400
SciProfiles: 2075801

Keywords

urothelial carcinoma, survival, disease recurrence, prognostic factors, urology

Countries

Serbia

Activities

Collapse all

Employment (2)

Univerzitetski klinički centar Srbije Klinika za urologiju: Beograd, Beograd, RS

Employment
Source: Self-asserted source
Bogomir Milojevic

Univerzitet u Beogradu Medicinski fakultet: Beograd, Beograd, RS

Employment
Source: Self-asserted source
Bogomir Milojevic

Education and qualifications (4)

Univerzitet u Beogradu Medicinski fakultet: Beograd, Beograd, RS

2020 to 2022 | oncology subspecialist (Institute of Oncology and Radiology, Belgrade, Serbia)
Education
Source: Self-asserted source
Bogomir Milojevic

Univerzitet u Beogradu Medicinski fakultet: Beograd, Beograd, RS

2012 to 2017 | Urologist (Clinic Of Urology, University Clinical Center of Serbia)
Education
Source: Self-asserted source
Bogomir Milojevic

Univerzitet u Beogradu Medicinski fakultet: Beograd, Beograd, RS

2007 to 2013 | PhD
Education
Source: Self-asserted source
Bogomir Milojevic

Univerzitet u Beogradu Medicinski fakultet: Beograd, Beograd, RS

2000 to 2006 | MD (medicinski fakultet )
Education
Source: Self-asserted source
Bogomir Milojevic

Peer review (41 reviews for 16 publications/grants)

Review activity for Bioengineering. (1)
Review activity for Biomedicines. (1)
Review activity for Cancers. (5)
Review activity for Complications (1)
Review activity for Current oncology. (3)
Review activity for Diagnostics. (3)
Review activity for Genes. (1)
Review activity for Healthcare. (1)
Review activity for International journal of molecular sciences. (2)
Review activity for International journal of translational medicine. (1)
Review activity for International urology and nephrology : (9)
Review activity for Journal of clinical medicine. (7)
Review activity for Life. (2)
Review activity for Medicina. (1)
Review activity for Pharmaceuticals. (1)
Review activity for Urologic oncology. (2)
How many people are using ORCID?